What's Happening?
Pendopharm, a division of Pharmascience Inc., has signed an exclusive distribution agreement with Neuraxpharm Group for Buccolam, a midazolam hydrochloride oromucosal solution, in Canada. Buccolam is approved by Health Canada for treating prolonged, acute convulsive seizures in children. This agreement allows Pendopharm to commercialize Buccolam in Canada, addressing the needs of pediatric epilepsy patients. The medication is designed for buccal administration, providing a ready-to-use solution for managing seizures effectively.
AD
Why It's Important?
The distribution agreement for Buccolam represents a significant advancement in epilepsy treatment for Canadian children. By providing a ready-to-use medication, Pendopharm aims to improve patient outcomes and reduce the need for emergency medical services during seizures. This development underscores the importance of addressing unmet medical needs in neurology and highlights Pendopharm's commitment to expanding access to essential medicines. The partnership with Neuraxpharm strengthens Pendopharm's position in the CNS market, potentially influencing future collaborations and product offerings.
